Using neutral language with patients and thorough documentation can help mitigate your practice’s legal risks when utilizing ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

Children with nontraumatic cataracts undergoing implantation of a secondary intraocular lens (IOL) after lensectomy are at a risk for complications including a diagnosis of glaucoma and visual axis ...